The U.S. Food and Drug Administration (FDA) launched a new pilot program on September 15, 2026, to reduce the time between identifying a potential medicine and beginning the first clinical trials in humans. The initiative, known as the Expedited Investigational New Drug (IND) Pilot Program, focuses on the preparation of applications for Phase 1 studies.
According to the FDA’s official announcement, pharmaceutical companies will be able to work with qualified research institutions, known as Qualified Research Institutions (QRIs). These organizations may support the scientific and regulatory preparation of IND submissions before a proposed study begins.
The program does not represent an early approval pathway for medicines. Companies will still be responsible for submitting the required nonclinical information, demonstrating manufacturing quality, designing the clinical protocol and protecting study volunteers. The pilot is intended to test whether the preparation and review process can become more coordinated without reducing existing safety and scientific requirements.
How the FDA expedited IND pilot will work
The central feature of the initiative is the possibility of submitting and reviewing parts of an IND application as they become ready. Rather than waiting for every component of the dossier to be completed, sponsors and participating institutions may engage with the FDA progressively during the preparation stage.
The agency says this approach could help identify technical, regulatory or safety issues earlier. It may also allow certain activities to proceed in parallel when appropriate, including ethics committee review and preparations at clinical research sites. The objective is to reduce delays caused by discovering problems only after an entire application has been assembled.
The FDA’s program page describes the pilot as part of broader efforts to modernize early- and late-stage clinical development. The agency’s model is focused specifically on the transition from preclinical research to the first study involving human participants.
Applications and initial selection
For the first round, the FDA expects to select between eight and 10 pairs consisting of a sponsor and a qualified research institution. Companies interested in participating must submit their applications by October 30, 2026, according to the agency’s published instructions.
The FDA expects to notify selected participants on December 18, 2026. However, the agency notes that the schedule may change depending on the volume of applications received. The application process is therefore limited to candidates that meet the program’s requirements and are evaluated by the regulator.
The initiative is designed to connect companies with institutions capable of supporting the scientific, operational and regulatory work required before a Phase 1 study can begin. It does not guarantee that an applicant will be accepted, that an IND will be cleared or that a product will eventually reach the market.
Why the initiative matters for drug development
Preparing an IND application is one of the most time-consuming stages in pharmaceutical development. The FDA has said that the interval between identifying a drug candidate and starting human trials can take as long as two years in the United States. The agency has also pointed to faster comparable processes in countries such as China and Australia.
By allowing earlier interaction with regulators and a more gradual review of documentation, the pilot could help sponsors identify obstacles before they become larger delays. The approach may be particularly relevant to pharmaceutical companies, academic medical centers, contract research organizations and other groups involved in early-stage biomedical innovation.
At the same time, the program’s impact will depend on how the participating teams use the process and whether the model produces measurable improvements without creating additional administrative burdens. Because it is a pilot, the initiative is intended to generate experience that can inform future decisions about the organization of clinical development in the United States.
A pilot, not a change to approval standards
The FDA’s initiative should not be interpreted as a relaxation of the standards used to protect clinical trial participants. A sponsor must continue to provide evidence supporting the proposed study, maintain appropriate manufacturing controls and meet the regulatory obligations associated with research involving humans.
The agency’s announcement establishes a limited test of a different workflow rather than a new guarantee for drug developers. Its value will be measured by whether early communication, qualified institutional support and staged document review can shorten preparation timelines while preserving the quality and reliability of the information submitted.
For the United States, the program also reflects the growing competition among countries to attract biomedical research and accelerate the development of new therapies. The first group of participating sponsor-institution pairs will provide the initial evidence of whether the FDA expedited IND pilot can make the start of clinical research more efficient without compromising safety.
